MyCare - Model My5-FU -Oncology Therapy Device

BSA dosing results in sub-target 5-FU levels in the majority of patients. PK- guided dosing can move 5-FU levels into the target range. Optimal dosing of 5-FU is associated with increased efficacy and reduced toxicity.